Differences in Pharmacological Potency

Human PPAR? binding

IC50 (nM ± SEM) 41 ± 18 7970 ± 580

Clinical dose (mg) 4 - 8 400 - 600

Binding affinity/agonist potency at PPAR? are highly correlated with antidiabetic potency

Rosiglitazone

Troglitazone